Dengue Vaccine Current Affairs - 2020

Sun Pharma signs deal with ICGEB to develop India’s first dengue vaccine

India’s largest pharmaceutical company Sun Pharma has signed deal with International Centre for Genetic Engineering and Biotechnology (ICGEB) for clinical development Cissampelos pariera (Cipa), India’s first vaccine (drug) for the treatment of dengue.

The partnership between Sun Pharma and ICGEB aims to develop` safe, effective and affordable botanical drug Cipa.

Key Facts

  • Under the deal, Sun Pharma will get access to all the intellectual properties (IP) rights of the drug across 17 countries.
  • ICGEB will establish assay systems for the development of Cipa for the treatment of dengue infection.
  • ICGEB had explored Indian traditional medicine, Ayurveda, to identify plants that could be a source of dengue inhibitory activity
  • In its research it was found that an alcoholic extract prepared from Cissampelos pareira Linn from C. pareira plant inhibits the replication of dengue viruses in living cells in culture.
  • Besides, alcoholic extract showed antipyretic and anti-inflammatory effects and protected mice against dengue infection.

Significance of the deal

India is dengue-endemic resource-poor country representing 50% of the global population estimated to be at risk of dengue virus. This will be for the first time a vaccine developed entirely in India for a vector-borne disease that has been advanced for clinical development in the country. The C. pareira plant may serve as a basic source for the development of an inexpensive herbal formulation against dengue.

About the International Centre for Genetic Engineering and Biotechnology (ICGEB)

  • ICGEB is an international, nonprofit research organization promoted by the United Nations Industrial Development Organization (UNIDO). It is part of the United Nations System.
  • It was established as a special project of UNIDO, but it became fully autonomous in 1994 and now counts over 60 Member States.
  • It provides a scientific and educational environment of highest standard and conducts innovative research in life sciences for the benefit of developing countries.
  • It strengthens the research capability of its Members through training and funding programmes and advisory services.
  • It also represents a comprehensive approach to promoting biotechnology internationally.

Philippines becomes first Asian country to approve sale of dengue vaccine Dengvaxia

Philippines became the first Asian country to approve the sale of the world’s first ever dengue vaccine Dengvaxia in the country.

The Dengvaxia vaccine has been manufactured by French pharmaceutical manufacturer Sanofi Pasteur. It has been designed to protect people in the 9-45 age groups from all four subtypes of the virus.

Key facts

  • The Dengvaxia vaccine was produced as the result of an extensive clinical development programme of the French company than ran for almost two decades. Sanofi Pasteur has requested authorisation to roll out the vaccine in 20 countries.
  • Earlier it secured its first regulatory approval in Mexico a fortnight ago and is currently being reviewed by around 20 countries in Asia and Latin America.
  • Clinical tests of the vaccine carried out on 40,000 people from 15 countries by the company has shown that vaccine can immunise two-thirds of people aged 9-45.
  • It was also found that the vaccine is capable of reducing the risk of hospitalisation of person infected by dengue virus by 80 percent.


It is hoped the vaccine could eventually help prevent millions of deaths from dengue which is considered as the world’s fastest growing mosquito borne disease mainly due to climate change. The World Health Organization (WHO) has mentioned that around 400 million people are infected worldwide every year by the dengue virus and two-thirds are in Asia.